$1.56−0.09 (−5.17%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Altimmune (ALT) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 99% below its peak, net margin −214861.0%. Worth your attention in FY25: Share count (+113.4%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($K)▲105.0%
41.0
FY21→FY25CAGR −68.9%/yr
Net income ($K)▲7.3%
−88,093.0
FY21→FY25CAGR —
Free cash flow ($K)▲15.4%
−67,546.0
FY21→FY25CAGR —
Diluted EPS▲25.4%
−1.00
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+113.4%
41.3mn → 88.1mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($K)
-214861¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 100.0% → 100.0%. Net margin -214861.0% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.4292, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 26.0 | 41.0 | 20.0 | 426.0 | −68.0 | 4,410.0 | ▲105.0% | −68.9% |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | 26.0 | 41.0 | 20.0 | 426.0 | −68.0 | 4,410.0 | ▲105.0% | −68.9% |
Research & development | 80,272.0 | 66,432.0 | 82,226.0 | 65,799.0 | 70,538.0 | 74,541.0 | ▼19.2% | −2.8% |
Selling, general & admin | 34,825.0 | 28,098.0 | 20,966.0 | 18,137.0 | 17,134.0 | 15,413.0 | ▲34.0% | +16.2% |
Total operating expenses | 115,097.0 | 94,530.0 | 103,192.0 | 96,355.0 | 87,672.0 | 101,324.0 | ▼8.4% | −1.7% |
Operating incomefeeds ROC rank | −115,071.0 | −94,489.0 | −103,172.0 | −95,929.0 | −87,740.0 | −96,914.0 | ▲8.4% | — |
Other income, net | 10,717.0 | 5,715.0 | 8,113.0 | 7,482.0 | 2,830.0 | −176.0 | — | — |
Pretax income | −104,354.0 | −88,774.0 | −95,059.0 | −88,447.0 | −84,910.0 | −97,090.0 | ▲6.6% | — |
Income tax | — | −681.0 | 0.0 | — | −197.0 | 0.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −104,354.0 | −88,093.0 | −95,059.0 | −88,447.0 | −84,713.0 | −97,090.0 | ▲7.3% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | — | −1.00 | −1.34 | −1.66 | −1.81 | −2.35 | ▲25.4% | — |
Diluted shares (mn) | — | 88.10 | 71.00 | 53.25 | 46.93 | 41.28 | ▲24.1% | +20.9% |
| Margins | ||||||||
Gross margin82nd pct in Healthcare | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | ▲0.0pp | +0.0pp |
Operating margin | −442580.8% | −230461.0% | −515860.0% | −22518.5% | 129029.4% | −2197.6% | ▲285399.0pp | −228263.4pp |
Net margin0th pct in Healthcare | −401361.5% | −214861.0% | −475295.0% | −20762.2% | 124577.9% | −2201.6% | ▲260434.0pp | −212659.4pp |
† TTM = trailing four quarters through 2026-09-30.
5 more years of statements and CSV export are on Premium, and 11 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-06 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Altimmune's revenue last fiscal year?
Altimmune reported revenue of $41.0K in fiscal 2025, up 105.0% from fiscal 2024.
What was Altimmune's net income?
Altimmune reported net income of −$88,093.0K in fiscal 2025, a net margin of −214861.0%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

